Healthcare - Biotechnology - NASDAQ - GB
$ 31.59
-3.16 %
$ 1.58 B
Market Cap
-34.34
P/E
CASH FLOW STATEMENT
2.94 M
OPERATING CASH FLOW
-5.42 M
INVESTING CASH FLOW
34.3 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immunocore Holdings plc
| Net Income | -55.3 M |
| Depreciation & Amortization | 4.09 M |
| Capital Expenditures | -5.42 M |
| Stock-Based Compensation | 32.5 M |
| Change in Working Capital | 5.78 M |
| Others | 21.7 M |
| Free Cash Flow | -2.48 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (55.3) | (41.2) | (131.5) | (74.1) | (103.9) | (71.6) |
| Depreciation & Amortization | 4.1 | 6.1 | 7.0 | 9.0 | 9.2 | 6.7 |
| Deferred Income Tax | 0 | (2.9) | (9.4) | (13.3) | (22.3) | (16.5) |
| Stock Based Compensation | 32.5 | 32.9 | 48.9 | 8.2 | 3.1 | 0.7 |
| Other Operating Activities | 15.9 | (7.4) | (14.9) | 38.5 | 22.6 | (3.4) |
| Change in Working Capital | 5.8 | (12.9) | (16.8) | (28.8) | (10.1) | 67.6 |
| Cash From Operations | 2.9 | (31.3) | (129.7) | (60.6) | (101.4) | (16.6) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (5.4) | (2.2) | (1.0) | (3.1) | (4.3) | (3.5) |
| Other Items | 0 | 2.4 | 0.5 | 3.5 | 0.1 | 61.6 |
| Cash From Investing Activities | (5.4) | 0.2 | (0.5) | 0.5 | (4.1) | 58.0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 45.1 | (4.0) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 34.3 | (1.3) | (10.6) | (0.1) | (0.7) | 0.1 |
| Cash From Financing Activities | 34.3 | 138.2 | 276.3 | 115.9 | 55.1 | 0.1 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 40.2 | 114.3 | 146.0 | 55.8 | (50.4) | 41.5 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (2.5) | (33.5) | (130.8) | (63.6) | (105.7) | (20.2) |